SubsidieMeesterscanceR agnOstic immUnoTherapy predIctioN blood-tEst
PamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment.
Projectdetails
Introduction
Cancer is the second leading cause of death worldwide, accounting for 10M deaths in 2020. Although 7 Immune Checkpoint Inhibitors (ICI) are approved for different cancer indications and have represented a true breakthrough, only 10-50% of advanced cancer patients respond to the treatment.
Challenges in ICI Treatment
This unpredictability of results, together with 15-60% severe toxicity rates and high prices, are restricting the impact potential of ICIs. Predicting ICI response is critical for fully realizing their potential in treating early-stage tumors and enhancing ICI treatment regimens.
PamGene’s IOpener
PamGene’s IOpener is a ground-breaking in vitro diagnostics testing platform for ICI response prediction.
Key Features
- Made possible by PamGene’s proprietary microarray-based kinase activity profiling of host immune cells.
- It can predict a patient’s response before ICI therapy is started from a simple blood draw.
Impact on Precision Medicine
The IOpener aims to revolutionize the precision medicine sector, enabling the widespread use of ICIs at any cancer stage.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.669.631 |
Tijdlijn
| Startdatum | 1-8-2023 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PAMGENE INTERNATIONAL BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC COG | € 1.993.875 | 2023 | Details |
Immunogenic cell death (ICD) in the cancer-immune dialogueThis project aims to enhance anticancer treatments by studying immunogenic cell death (ICD) mechanisms and developing strategies to improve tumor immunosurveillance through dendritic cell activation. | ERC ADG | € 2.500.000 | 2023 | Details |
EXPANDing Immune Cells and their Tumor Antigens during checkpoint immunotherapyEXPAND IT aims to uncover the mechanisms of T-cell and B-cell expansion in the tumor microenvironment during cancer immunotherapy to enhance patient responses and develop new therapies. | ERC ADG | € 2.500.000 | 2023 | Details |
The development of a predictive biomarker for immunotherapy outcome based on flow cytometry testThe project aims to develop a flow cytometry-based predictive biomarker for immunotherapy response, enhancing personalized treatment and aiding pharmaceutical R&D through the detection of immunotherapy-responsiveness cells (IRCs). | ERC POC | € 150.000 | 2022 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Immunogenic cell death (ICD) in the cancer-immune dialogue
This project aims to enhance anticancer treatments by studying immunogenic cell death (ICD) mechanisms and developing strategies to improve tumor immunosurveillance through dendritic cell activation.
EXPANDing Immune Cells and their Tumor Antigens during checkpoint immunotherapy
EXPAND IT aims to uncover the mechanisms of T-cell and B-cell expansion in the tumor microenvironment during cancer immunotherapy to enhance patient responses and develop new therapies.
The development of a predictive biomarker for immunotherapy outcome based on flow cytometry test
The project aims to develop a flow cytometry-based predictive biomarker for immunotherapy response, enhancing personalized treatment and aiding pharmaceutical R&D through the detection of immunotherapy-responsiveness cells (IRCs).